The SYNTap Test, a new biomarker test to help diagnose diseases like Parkinson’s, Lewy body dementia and Multiple System Atrophy, is now on the…
Eyes are on a water retention drug called bumetanide after a recent study showed it was correlated with a lower risk of Alzheimer’s in…
An emerging brain technology offers a non-invasive way to change the brain for the better, using magnets. Hailed as affordable, painless, and convenient, transcranial…
Nikki Schultek, founder of the global medical research consortium Intracell Research Group, takes a close look at how the COVID-19 pandemic may prompt a…
Two first-of-their-kind studies presented at the Alzheimer’s Association International Conference show transgender and nonbinary adults are more likely show early possible signs of dementia….
In light of last week’s long-awaited FDA decision on experimental Alzheimer’s treatment aducanumab, a panel of clinical trials experts looks at why Alzheimer’s drug…
The FDA is expected to decide whether or not to approve Biogen and Eisai’s experimental Alzheimer’s drug, aducanumab, in less than a week. Geri…